BTK inhibitors get a boost

Nature Reviews Drug Discovery 16, 818 (2017). doi:10.1038/nrd.2017.250 Author: Asher Mullard The FDA granted accelerated approval to AstraZeneca and Acerta Pharma's acalabrutinib for mantle cell lymphoma, a second approval for the BTK inhibitor class. The agency approved AbbVie and Janssen's first-in-class BTK inhibitor, ibrutinib, in 2013 for the same indication. Ibrutinib has since picked up
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Tags: News and Analysis Source Type: research